📰 Featured highlight! Our Chief Medical Officer Maria L Escolar, MD, MS, was recently interviewed by CGTLive about navigating the novel drug development journey for patients with Krabbe disease, a rare leukodystrophy, and the importance of newborn screening for rapid identification and treatment. Read more here ➡️ https://bit.ly/4bBmpva
Forge Biologics
Biotechnology Research
Columbus, Ohio 18,990 followers
A member of Ajinomoto Bio-Pharma Services
About us
Forge, a member of Ajinomoto Bio-Pharma Services, is a gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality. We partner with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups. We bring expertise in gene therapy manufacturing and therapeutics development to the table, helping champion teams that are navigating the long road from the lab bench to the bedside. With a patients-first approach, we are forging new models for working together to better accelerate these transformative medicines to reach those who need them most.
- Website
-
http://www.forgebiologics.com
External link for Forge Biologics
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Columbus, Ohio
- Type
- Privately Held
- Founded
- 2020
- Specialties
- AAV, Gene Therapy, Biotech, and cGMP
Locations
-
Primary
Columbus, Ohio, US
Employees at Forge Biologics
Updates
-
Our quality-by-design HEK293 Ignition Cells™ and pEMBR™ Ad Helper Plasmid allow us to deliver more efficient services to gene therapy developers. Here's how 👇 Ignition Cells™: • Applicable across a wide variety of indications, serotypes, and stages of development • Well-documented history with regulatory feedback • Fully qualified Master Cell Bank and Working Cell Bank produced at Forge • >90% full capsid post-enrichment with CsCl, with undetectable empty particles • Used by >95% of clients pEMBR™ Ad Helper Plasmid: • Immediately available at research and phase I/II GMP-Pathway grades • Shows equivalent AAV yields as compared to commercially available alternatives • Improved safety profile, engineered to reduce known immunogenic elements • Decreased size increases efficiency in manufacturing • Used by >80% of clients
-
-
We’re hiring! Our award-winning culture and excellent benefits make Forge a standout workplace. We offer flexible PTO, paid parental leave, a flexible work environment, and more! We are a team of diverse, driven, and passionate people working together to trailblaze a new model for how medicines are made to treat patients with genetic diseases. Explore our open positions and start or continue your gene therapy career here ➡️ https://bit.ly/3xLdcTi
-
-
Forge's Ignite interns are on fire this summer! From leading critical projects to volunteering and professional development, they’re gaining an invaluable experience. Hear from Pedro Vera Perez, our Process Development Intern, about the soft skills he's honed so far. 👇
-
📰 Want to stay up-to-date on our “viral” news? Subscribe to receive the latest news, offerings, and updates from Forge ➡️ https://bit.ly/3zo6Aef
-
As the Tour de France races on, join us for a "Tour de Forge!" Our unique end-to-end AAV and plasmid manufacturing services guide developers to success at every stage of development. Discover our capabilities ➡️ https://bit.ly/4cnYYqE
-
-
Today is International Neonatal Screening Day. Newborn screening is critical for the early detection of many genetic diseases, providing accurate diagnoses and ensuring rapid referrals within the first few weeks of life. For patients with Krabbe disease, newborn screening is essential. It significantly reduces the time to access vital treatments, which is crucial for their health outcomes. Thanks to the advocacy efforts of patient families and organizations, more states now include Krabbe disease on their newborn screening panels or have RUSP (recommended uniform screening panel) alignment legislation. Learn more about the importance of neonatal screening here ➡️ https://hubs.li/Q02DHcfM0
-
-
Don’t miss our Chief Business Officer, Magdalena Tyrpien, on the Endpoints News LGBTQ+ Leaders in Biopharma webinar! Magdalena will join other distinguished panelists to celebrate and discuss their perspectives on inclusion and bridging the gap for underrepresented communities. Check out the details below 👇 📅 Today, June 27th ⏰ 11 am 📍 Register for the webinar here ➡️ https://hubs.li/Q02DtyWw0
-
-
Forge’s Chief Medical Officer, Maria L Escolar, MD, MS, will be presenting a poster at the 10th Congress of the European Academy of Neurology June 29th-July 2nd, marking our first year at this conference. Dr. Escolar will be presenting an electronic poster on “REKLAIM, a Novel Phase Ib Clinical Trial of Intravenous FBX-101 (AAVrh10.GALC) After UCBT for Infantile Krabbe Disease.” Learn more about the conference here ➡️ https://hubs.li/Q02DpJjf0
-